Anti-Inflammatory Oxysterol, Oxy210, Inhibits Atherosclerosis in Hyperlipidemic Mice and Inflammatory Responses of Vascular Cells
These findings suggest that Oxy210 could be a drug candidate for targeting both NASH and atherosclerosis, as well as chronic inflammation associated with the manifestations of metabolic syndrome.
Authors
- Simon T. Hui (ORCID: https://orcid.org/0000-0003-3540-3013)
- Lia Farahi (ORCID: https://orcid.org/0000-0002-4599-1050)
- Aldons Jake Lusis (ORCID: https://orcid.org/0000-0001-9013-0228)
- Andrew J. Fleetwood (ORCID: https://orcid.org/0000-0002-6803-3533)
- Frank Stappenbeck
- Farhad Parhami (ORCID: https://orcid.org/0000-0002-3312-294X)
- Andrew James Murphy (ORCID: https://orcid.org/0000-0001-7039-7777)
- Nigora Mukhamedova (ORCID: https://orcid.org/0000-0002-5924-1816)
- Feng Wang
- Satyesh K. Sinha (ORCID: https://orcid.org/0000-0002-8735-6303)
- Dmitri Sviridov (ORCID: https://orcid.org/0000-0002-8366-3832)
Institutions
- Baker Heart and Diabetes Institute (AU)
- University of California, Los Angeles (US)
- Max Biopharma (United States) (US)
- Monash University (AU)
Publication Details
- Journal
- Cells
- Published
- 2024-09-30
- DOI
- https://doi.org/10.3390/cells13191632
- Citations
- 6
- Primary Topic
- Cholesterol and Lipid Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 3.44
Funders
- National Heart, Lung, and Blood Institute
- National Institute of Diabetes and Digestive and Kidney Diseases